Conference abstract
Conference abstractPublished 2018
Tumor liberated protein (TLP) as potential vaccine for lung cancer patients
Foundation de Beaumont Bonelli for cancer research, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Previous studies have investigated the potential role of blood-based tumor markers for early detection, diagnosis, prognostication, post-operative follow-up as well as monitoring of tumor burden and response to treatment in advanced disease stages. To date, the most commonly used markers include neuron specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1) and cancer antigen CA 125 (CA 125). However, low sensitivity, specificity or reproducibility limit their clinical utility in the care of patients with lung cancer and no single marker has gained widespread acceptance as diagnostic test, prognostic indicator or monitor of treatment response. Ideally, a tumor marker should have a sensitivity and specificity of 100%, a goal that is almost never achieved. In 1983, a tumor-associated antigen was isolated from NSCLC and named tumor liberated protein (TLP). The immunohistochemical analysis revealed a cytoplasmic localization of TLP in small and larger granules. In some specimens it was also detected in the lumen of atypical glands and in the bronchial secretions, suggesting that TLP could be considered a secretory product of neoplastic cells. Tarro et al. have demonstrated that when TLP is extracted from a patient’s tumor, purified in the laboratory and reintroduced into the body, it boosts an immune response in the host. The partial sequence analysis of this protein led to the synthesis of corresponding antigenic peptides that have been used to produce antisera in rabbits. According to Tarro et al., four TLP-derived peptides were identified: RTNKEASI, GSAXFTN, QRNRD and GPPEVQNAN. Anti- RTNKEASI rabbit sera reacted specifically with NSCLC tumor extracts as well as sera from lung cancer patients. TLP was detected in sera of 53.1% of NSCLC patients (N = 534) with 75% being positive in the early stage (stage I) dropping to 45% in the late stage (stage IV), suggesting a potential role as early screening biomarker.
Subjects
MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Tumor liberated protein (TLP) as potential vaccine for lung cancer patients
Conference abstract · 29 Oct 2012
Tumor Liberated Protein (TLP) and human corine in lung cancer cells: Homology or different isoforms in the sequence at the cytoplasmic surface
Conference abstract · 29 Oct 2012
Tumor Liberated Protein (TLP) from lung cancer and perspectives for immunotherapy
Conference abstract
From sequence of tumor liberated protein to potential targets for diagnosis and therapy
More from this journal
The newest in Medical Microbiology Reports.
Commentary · 26 Dec 2023
Analyzing the Spectrum of Pathogen Interactions and their Effects
Short communication · 26 Dec 2023
Managing the Obstacles and Advances of Virological Analysis
Opinion · 26 Dec 2023
Exploring Morphological Diversity in the Natural World
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedical Microbiology Reports
- SubjectMicrobiology
- BylineArticles whose byline prints “Giulio Tarro”

